Comparative Study Of Injection Triamcinolone And Hyaluronidase Combination With Injection Platelet Rich Plasma (PRP) In Management Of Oral Submucous Fibrosis

Introduction: Oral sub mucous fibrosis (OSMF) is an oral precancerous condition and chances of transformation in to malignancy is 1.5-15%. It is  characterized by inflammation and progressive fibrosis of the submucosal tissue resulting in marked rigidity and trismus. Objective: The objective of this study aimed to compare the results of Injection Triamcinolone and Hyaluronidase Combination with Injection Platelet Rich Plasma (PRP)in the management of oral submucous fibrosis. Methodology: This comparative study was conducted at Bolan Medical Complex Hospital quetta and Bakhtawar Amin Medical and Dental College duration 2022 Jan to September 2024. Patients in group A received a combination of triamcinolone and Hyaluronidase in group B PRP (platelets rich plasma) injected intralesionally in fibrosis of OSMF, once a week. Results: Data were collected from 60 patients with mean age of patients in both groups was similar, with 42.5 ± 9.3 years in Group A and 41.8 ± 8.7 years in Group B. The duration of symptoms was slightly longer in Group A (3.8 ± 1.5 years) compared to Group B (3.6 ± 1.7 years), though not significantly different. Group A (Triamcinolone + Hyaluronidase) saw a reduction in the baseline pain score from 7.2 to 3.1, representing a 56.9% decrease in pain. Group B (PRP), however, exhibited a more pronounced reduction, with pain scores dropping from 7.0 to 1.9, resulting in a 72.9% decrease. Conclusion: It is concluded that Injection Platelet Rich Plasma (PRP) is a more effective and safer treatment option than the combination of Triamcinolone and Hyaluronidase for managing Oral Submucous Fibrosis (OSMF). PRP demonstrated superior outcomes in improving mouth opening, reducing pain, and enhancing patient satisfaction, with fewer side effects and lower recurrence rates.